GlassScriptPhysician profile
Gary Wilbur Clauser
NPI 1598773038
$517,966.45
in general payments reported to CMS, 2019-2025
15 companies · $60K in 2025
The $60K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173K · 2020: $65K · 2022: $91K · 2023: $58K · 2024: $71K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $169K · Consulting Fee: $12K · Food and Beverage: $7,066 · Travel and Lodging: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $169,003.00 |
| Consulting Fee | $11,590.00 |
| Food and Beverage | $7,066.14 |
| Travel and Lodging | $1,376.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $177,221.68 | 2019-2025 | Mavenclad, Mavenclad, Evobrutinib |
| Biogen, INC. | $81,902.60 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Genzyme Corporation | $77,092.68 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $57,979.84 | 2022-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $43,971.20 | 2019-2024 | |
| Celgene Corporation | $30,719.44 | 2019-2025 | Zeposia |
| Tg Therapeutics, INC. | $23,116.97 | 2024-2025 | |
| Genentech USA, INC. | $11,796.13 | 2019 | |
| Allergan, INC. | $5,618.06 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $4,892.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $2,224.55 | 2022 | |
| Janssen Scientific Affairs, LLC | $1,320.00 | 2020 | |
| Horizon Therapeutics Plc | $62.75 | 2022-2023 | Uplizna |
| Mallinckrodt Hospital Products INC. | $32.00 | 2020 | |
| Supernus Pharmaceuticals, INC. | $16.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Clauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.